The pharmacokinetics of ceftazidime after a 1-g bolus dose were studied in six elderly volunteers and 12 young subjects. Serum and urine samples were collected in serial order for 24 h and assayed by high-pressure liquid chromatography. The ceftazidime renal clearance was reduced in elderly subjects, a symptom related to normal aging of the kidneys. The decrease in volume of distribution in the elderly group may be explained by a reduction in total body water and an increase in fat tissue. Dosage adjustment is probably not necessary for otherwise healthy elderly patients requiring ceftazidime.
Most of the observed altered antimicrobial efficacy in the elderly is probably caused by a change in pharmacokinetic patterns. Since there is an increased risk of infection observed with normal aging, there is an urgent need to learn more about the pharmacokinetics of antimicrobial agents in the geriatric population. Recently, two groups reported on the pharmacokinetics of ceftazidime in acutely ill elderly patients; both reported a prolonged half-life of ceftazidime in old age (5, 6 ). The present study was designed to evaluate ceftazidime kinetics in young subjects and the influence of normal aging on its kinetics.
Our population consisted of six healthy elderly males ranging in age from 51 to 75 years (mean age, 65.2 years) and 12 young subjects (six men and six women) ranging in age from 19 to 29 years (mean age, 22.9 years). Individuals with renal disease as determined by elevated serum creatinine (greater than 2.0 mg/dl), subjects taking any chronic medications, and those with known or suspected hypersensitivity to penicillins or cephalosporins were excluded. All subjects were judged healthy on the basis of physical examination, medical history, and laboratory examinations.
After informed consent was obtained, subjects were given 1.0 g of ceftazidime intravenously over 5 min. Blood samples were collected at 0, 5, 15, 30, and 45 min and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 , and 24 h after ceftazidime administration. For technical reasons, the 5-min sampling was not performed in elderly subjects. Urine specimens were collected before ceftazidime administration and at 0 to 2, 2 to 4, 4 to 8, 8 to 12, and 12 to 24 h. All serum and urine samples were frozen at -20°C until assayed. Assays of young and elderly volunteer samples were performed under the same conditions. High-pressure liquid chromatography was performed with a Waters Novapak C18 (radial pack) column. The mobile phase consisted of 90% ammonium phosphate buffer (pH 5.6) and 10% methanol. A Waters Quality Analyzer 1 was used at a flow rate of 1.0 ml/min, and the effluent was monitored by UV absorbance at 254 nm. Serum protein precipitation was performed by mixing 0.5 ml of sample with 250 ,ul of 10% trichloroacetic acid containing of ceftizoxime (33 ,ug/ml) as the internal standard. The supernatant (3 ,ul) was injected onto the column. Urine samples were prepared in a similar manner after diluting the samples 10-to 100-fold with distilled water. The sensitivity limit of the assay was 0.75 .Lg/ml of serum. The coefficient of variation from day to day was less than 5.5%. Linear regression analysis of the * Corresponding author. E 10. 1 and 100 ,ug/ml. Subject serum concentration-time data were individually analyzed by a nonlinear regression program (7), and we used a residual method for determining initial estimates (4). A two-compartment pharmacokinetic model generally fitted the data best, with the exception of three subjects for which a one-compartment model was used. This decision was made on the basis of visual inspection and the Fisher (F) ratio test described by Boxenbaum et al. (1) . Ceftazidime clearance was calculated as the ceftazidime dose divided by the area under the concentration-time curve (AUC). AUC from time zero to infinity was calculated with conventional linear trapezoidal and extrapolation methods. Renal clearance was determined by the amount of ceftazidime excreted unchanged over 10 or 24 h in urine divided by AUC from 0 to 10 h or 0 to 24 h, respectively. Volume of distribution (Varea) was determined with noncompartmental analysis (3). Comparative statistical analysis was performed with one-way analysis of variance (11) . Figure 1 shows the mean serum ceftazidime concentrations in the elderly and young subjects after a single intravenous dose. A description of the subjects and pharmacokinetic parameters are presented in Table 1 . Elderly subject 4 is mainly responsible for skewing the data; he is the oldest volunteer and presented a serum creatinine concentration of 1.7 mg/dl. His creatinine clearance was estimated at 55.5 ml/min per 1.73 m2 by the Cockroft and Gault formula (2) . This volunteer exhibited a particularly long half-life (9.0 h). We could also detect ceftazidime in the serum of this subject 24 h after the administration. These aberrant results cannot be explained by technical bias or assay errors, and this subject should be considered as an outlier on statistical basis. Therefore, we elected to discard this data for statistical analysis. Thus, the mean pharmacokinetic data in Table  1 represent the other five elderly subjects and the 12 young volunteers.
Elimination half-life of ceftazidime was not statistically different in both groups. This is in contrast with preliminary data from Ljungberg and Nilsson-Ehle and the study of Naber et al., who demonstrated an increased ceftazidime half-life in their acutely ill elderly patients (5, 6 ). Ljungberg and Nilsson-Ehle explained this change by the physiological aging of the kidneys, although renal clearance was not significantly different (5) . It should also be noted that in these two studies, ceftazidime half-life in the elderly patients was at the upper end of the range for healthy adult subjects (5, 6, 8) . In our study, ceftazidime renal clearance was significantly lower in the elderly group and was responsible for a decreased ceftazidime total clearance observed. The volume of distribution (Varea) was much smaller in the aged volunteers: 0.180 versus 0.310 liters/kg for the young subjects (P < 0.001). Age-related decremnents in serum albumin concentration may not explain the change in. the volume of distribution with ceftazidime, since this cephalosporin is only 5 to 23% protein bound (8) . Since cephalosporins are exclusively confined to extracellular fluid, the reduction in lean mass and total body water observed in old age may be responsible for this decrease in the volume of distribution (9, 10) .
If we except the longer ceftazidime half-life and the AUC observed by Ljundberg and Nilsson-Ehle and Naber et al. in elderly patients, other pharmacokinetic data were similar, namely, total and renal clearance and percent urinary recovery. It should be emphasized that, in contrast with the two previous studies, our elderly subjects were ambulatory and had normal renal function. The patients studied by Ljundberg and Nilsson-Ehle were acutely ill with suspected septicemia, pneumonia, or febrile soft tissue infections (5).
Naber et al. enrolled elderly patients from an urological ward, who had complicated or hospital acquired urinary tract infections (6) . The age-related changes in kinetics that were present in our population would probably be greater in an older population characterized by chronic illness or malnutrition.
In conclusion, the normal age-related changes in ceftazidime kinetics were relatively small, and dosage adjustment is probably not necessary for elderly subjects requiring ceftazidime. However, in geriatric patients who are actually ill, debilitated, or malnourished or who have marked impairment of renal function, the dosage of ceftazidime may have to be reduced.
